Longeveron
LGVN | NASDAQ
$2.14
-$0.35 (-14.06%)
At close: Nov 16, 2026, 4:00 PM ET
$2.14
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Longeveron Company Profile
Company profile explainedCompany Profile
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Key Executives
| Name | Position |
|---|---|
| Stephen H. Willard | Chief Executive Officer & Director |
| Devin Blass | Chief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls |
| Brian Rash | Vice President of Research & Discovery |
| Joshua Michael Hare FACC | Co-Founder, Chief Science Officer & Executive Chairman |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Marie Washburn | Vice President & Corporate Controller |
| Nataliya Agafonova | Chief Medical Officer |
| Nirav Suresh Jhaveri | CFO and Principal Financial & Accounting Officer |
| Paul T. Lehr | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 10, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Longeveron
| Country | United States |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Stephen H. Willard |
Contact Details
Life Science & Technology Park Miami,
Florida 33136 United States
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L302 |
| ISIN Number | US54303L3024 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove LGVN